+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CytoDyn Inc - logo

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man. The company is based in Vancouver, Washington.

From
From
From
From
Psoriasis (Immunology) - Drugs In Development, 2021 - Product Thumbnail Image

Psoriasis (Immunology) - Drugs In Development, 2021

  • Report
  • July 2021
  • 1178 Pages
From
From
From
From
From
Autoimmune Hepatitis - Pipeline Insight, 2021 - Product Thumbnail Image

Autoimmune Hepatitis - Pipeline Insight, 2021

  • Clinical Trials
  • July 2021
  • 60 Pages
From
From
From
From
From
Leronlimab (CytoDyn) Drug Overview 2019 - Product Thumbnail Image

Leronlimab (CytoDyn) Drug Overview 2019

  • Report
  • June 2019
  • 14 Pages
Ovarian Cancer (Oncology) - Drugs in Development, 2021 - Product Thumbnail Image

Ovarian Cancer (Oncology) - Drugs in Development, 2021

  • Report
  • December 2021
  • 5066 Pages
From
Colon Cancer (Oncology) - Drugs in Development, 2021 - Product Thumbnail Image

Colon Cancer (Oncology) - Drugs in Development, 2021

  • Report
  • December 2021
  • 1498 Pages
From
Loading Indicator